Stock Events

Stock Events

Clearmind Medicine 

0
49
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.47MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CWY1.MU. It's not an investment recommendation.
Apple
10
AAPL
Alphabet
10
GOOGL
Tesla
8
TSLA
NVIDIA
8
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.65B
COMPASS Pathways is focused on psilocybin therapy for mental health conditions, competing in the psychedelic medicine sector alongside Clearmind Medicine.
AtaiBeckley
ATAI
Mkt Cap2.73B
ATAI Life Sciences is a biotech company developing treatments for mental health disorders, including psychedelic and non-psychedelic compounds, making it a competitor in the broader mental health treatment market.
GH Research
GHRS
Mkt Cap1.57B
GH Research is developing 5-MeO-DMT therapies for depression, a direct competitor in the psychedelic treatment market for mental health, similar to Clearmind's objectives.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness is engaged in the development of psychedelic therapies and wellness services, competing in the same sector as Clearmind Medicine.
MiniMed Group
MMED
Mkt Cap5.54B
MindMedicine (MindMed) Inc. is another key player in the psychedelic medicine space, focusing on developing treatments for mental illness and addiction, directly competing with Clearmind Medicine.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics is exploring the use of psychedelics in treatments, including psilocybin for substance abuse, positioning it as a competitor in the psychedelic therapy market.

About

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
Show More
CEO
Adi Zuloff-Shani
Employees
2
Country
Canada
ISIN
CA1850537095
WKN
000A42NQB

Listings

BOATS
BOATS
CMND.BOATS
STU
DE
CWY0.STU
F
DE
CWY1.F
MU
DE
CWY1.MU

0 Comments

Share your thoughts

FAQs

What is Clearmind Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Clearmind Medicine stocks are traded under the ticker CWY1.MU.
What is Clearmind Medicine revenue for the last year?▼
Clearmind Medicine revenue for the last year amounts to 0 EUR.
What is Clearmind Medicine net income for the last year?▼
CWY1.MU net income for the last year is -3.47M EUR.
How many employees does Clearmind Medicine have?▼
As of October 8, 2026, the company has 2 employees.
In which sector is Clearmind Medicine located?▼
Clearmind Medicine operates in the Health & Wellness sector.
When did Clearmind Medicine complete a stock split?▼
Clearmind Medicine has not had any recent stock splits.
Where is Clearmind Medicine headquartered?▼
Clearmind Medicine is headquartered in Vancouver, Canada.